WO2007066794A1 - Animal non humain a inactivation du gene brak - Google Patents
Animal non humain a inactivation du gene brak Download PDFInfo
- Publication number
- WO2007066794A1 WO2007066794A1 PCT/JP2006/324622 JP2006324622W WO2007066794A1 WO 2007066794 A1 WO2007066794 A1 WO 2007066794A1 JP 2006324622 W JP2006324622 W JP 2006324622W WO 2007066794 A1 WO2007066794 A1 WO 2007066794A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- brak
- human animal
- mice
- human
- mouse
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 46
- 101000858068 Homo sapiens C-X-C motif chemokine 14 Proteins 0.000 claims abstract description 6
- 238000012360 testing method Methods 0.000 claims description 83
- 238000000034 method Methods 0.000 claims description 74
- 210000000593 adipose tissue white Anatomy 0.000 claims description 61
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 57
- 206010022489 Insulin Resistance Diseases 0.000 claims description 52
- 239000000126 substance Substances 0.000 claims description 50
- 239000005557 antagonist Substances 0.000 claims description 44
- 208000008589 Obesity Diseases 0.000 claims description 33
- 235000020824 obesity Nutrition 0.000 claims description 33
- 230000000694 effects Effects 0.000 claims description 25
- 238000012216 screening Methods 0.000 claims description 19
- 230000002829 reductive effect Effects 0.000 claims description 12
- 241000283984 Rodentia Species 0.000 claims description 6
- 102100025250 C-X-C motif chemokine 14 Human genes 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 description 131
- 241000699666 Mus <mouse, genus> Species 0.000 description 82
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 72
- 210000002540 macrophage Anatomy 0.000 description 52
- 235000009200 high fat diet Nutrition 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 37
- 239000008280 blood Substances 0.000 description 37
- 102000004877 Insulin Human genes 0.000 description 36
- 108090001061 Insulin Proteins 0.000 description 36
- 229940125396 insulin Drugs 0.000 description 36
- 238000011813 knockout mouse model Methods 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 28
- 235000021590 normal diet Nutrition 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 25
- 230000014509 gene expression Effects 0.000 description 24
- 230000002950 deficient Effects 0.000 description 22
- 238000010586 diagram Methods 0.000 description 22
- 239000003925 fat Substances 0.000 description 22
- 239000012634 fragment Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 108010076365 Adiponectin Proteins 0.000 description 19
- 102000011690 Adiponectin Human genes 0.000 description 19
- 230000008569 process Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 238000010835 comparative analysis Methods 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 16
- 108010012236 Chemokines Proteins 0.000 description 15
- 238000013116 obese mouse model Methods 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 238000011830 transgenic mouse model Methods 0.000 description 14
- 102000019034 Chemokines Human genes 0.000 description 13
- 241000699660 Mus musculus Species 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 230000006870 function Effects 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 101100222386 Mus musculus Cxcl14 gene Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 238000011740 C57BL/6 mouse Methods 0.000 description 7
- 210000000577 adipose tissue Anatomy 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000004925 denaturation Methods 0.000 description 7
- 230000036425 denaturation Effects 0.000 description 7
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 210000002027 skeletal muscle Anatomy 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 239000008223 sterile water Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 210000004291 uterus Anatomy 0.000 description 7
- 108010053187 Diphtheria Toxin Proteins 0.000 description 6
- 102000016607 Diphtheria Toxin Human genes 0.000 description 6
- 108091008611 Protein Kinase B Proteins 0.000 description 6
- 210000001789 adipocyte Anatomy 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 239000012295 chemical reaction liquid Substances 0.000 description 5
- 238000012854 evaluation process Methods 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000001617 migratory effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108050006947 CXC Chemokine Proteins 0.000 description 4
- 102000019388 CXC chemokine Human genes 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 102100034599 Angiopoietin-related protein 6 Human genes 0.000 description 3
- 101710085819 Angiopoietin-related protein 6 Proteins 0.000 description 3
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 101000775476 Mus musculus Adiponectin Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000010240 RT-PCR analysis Methods 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- -1 antibodies) Proteins 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 238000007824 enzymatic assay Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000001215 fluorescent labelling Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 238000007446 glucose tolerance test Methods 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000006362 insulin response pathway Effects 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 101000858070 Mus musculus C-X-C motif chemokine 14 Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000472 morula Anatomy 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000000131 Beta tubulin Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 101150073122 CXCL14 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 101100222385 Homo sapiens CXCL14 gene Proteins 0.000 description 1
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 101150041215 JNK gene Proteins 0.000 description 1
- 108010081657 Ki antigen Proteins 0.000 description 1
- 102100030874 Leptin Human genes 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 102000002569 MAP Kinase Kinase 4 Human genes 0.000 description 1
- 108010068304 MAP Kinase Kinase 4 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100134024 Mus musculus Lat2 gene Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102100027441 Nucleobindin-2 Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 108010015181 PPAR delta Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102100031298 Proteasome activator complex subunit 3 Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940127004 drugs for type 2 diabetes Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000022275 macrophage chemotaxis Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000028550 monocyte chemotaxis Effects 0.000 description 1
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000006354 stress signaling Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
Definitions
- This book relates to knockout objects in which the BRA gene has been destroyed, the BRA attack skunk method using this, and the B antass operation method.
- mice that destroyed T or its body the instinct due to obesity was improved (ys T e a ⁇ , a e Vo 389 p ⁇ 60 614 997).
- BRA Beas ad Noe exp essed Che oe
- BRA Beas ad Noe exp essed Che oe
- Cain genes have been found to be colored in dairy color bodies. These chis are composed of 92 to 99 amino acids (8,000 to 0000), each with 4 stay-fitting stays. This is a characteristic of this stadium tomb and its 25-sided anomaly.
- Cain is classified into C, XC, and CX CC 4 groups based on this characteristic (Z ok A e ⁇ , y Vo 2, ⁇ 2 27 2000). Therefore, XC chi has been classified into 6 types so far, and by the absence of G e 9 (ER) in, E R + XC Kai ER CXC Cain. Belongs to CXC Cain that does not have an ER sequence, and is named CXC 4 because of its name.
- B has an activity of being specifically activated by B and prostaglandin E (K e a Ex ed Vo 94 85586 200).
- B is the sphere and the pre-differentiated
- B is a key that has a property not before the T cell and B, but before the organizational charge (K e ⁇ ⁇ Ex ed ⁇ , vo 94, ⁇ 85586 200). , No other known XC Y with the same spectrum.
- the problem that Ming solves is to clarify the sexuality and K of white spheres and kufa, and to analyze the lamellar state of obesity-induced lesions of BA genes. To provide the qualified items. In addition, it is to provide a method for squeezing BR antass and B antass using this material.
- Examples of humans include those that are in the state of becoming obese when they are in the state of obesity and those in which the number of cases of being in the state of becoming obese are reduced.
- examples of the above-mentioned article include an article, and examples of the article include a us.
- a B-attack song that is described in E () is used as a control substance, and a substance other than a substance is treated as a substance, and the substance and the substance are put into a state. And a step of administering a quality to the animal, and a step of evaluating the animal and the condition of the animal.
- A is a diagram related to the establishment of the BRA knockout system. The construction of the targeting vector and the UBSBRA locus after homologous recombination
- the position is shown schematically.
- the box () indicates the BRA gene's Xon component.
- P P2 is the position of the PCR ply used for ES cells.
- B is a diagram showing the establishment of the BRA knockout system.
- C is a diagram showing the establishment of the B knockout system.
- Ta RA was extracted from Us (), Us (), Us (), Lung and (), and tested for BR RA by Northern Butty. ac is the amount of RA on the surface.
- 2A is a diagram of the shape of a geneus. Each of the wild (), (), and () male parts of the wild was identified.
- 2B is a diagram of the shape of a geneus. The weight of the genius Uss was raised for 14 days.
- 2C is a diagram of a generous shape. Shows that the geneus is usually grown in 6 or 5). The graph shows the mean and quasi-error of. 2D is a diagram of the shape of a geneus. Indicates that the geneus is usually raised in 6 or 5). The graph shows the mean error.
- 2E is a diagram of the shape of a geneus. Indicates the weight of the device when the geneus is normally grown at 6 or (5). The graph shows the mean quasi-error of.
- Figure 2 shows the shape of the geneus. Shows a a ac (ac ”) separated from the enclosure of a normal genera (usage of 6 or 5) of the gene. The graph shows the mean quasi-error.
- Figure 3 is a diagram of Us's. Line pieces of A C) D woven weave woven from A B or C D were prepared, and 480 bodies were used as primary bodies for coloring. The brown CIGNA indicates the location of F480 sex cells.
- Fig. 4B is a diagram related to the ins test of the geneus.
- Fig. 4C is a diagram of a grape of Geneus (with a gusset). The mice grown in (RD) or (D 6) were allowed to stand overnight and then exposed to glucose. The (g) of grapes was determined. Rarely littered with
- 5A is a diagram for the gene Ushomon.
- Muss which are genes grown in (6, or 5), were collected, and the abundance of the wass was measured by ESA.
- the graph shows the mean error of the group.
- 5B is a diagram of the gene's hom.
- 5C is a diagram of the gene's hom.
- the genes grown in 6) or 5) were collected, and the amount of adipectin was determined by E.
- the graph shows the mean quasi-error of.
- 5D is a diagram about the homo of Geneus.
- 5E is a diagram of the gene's hom.
- the degree of susceptibility raised in (), () and 6 () 5 was determined by a quantitative kit.
- the graph shows the mean quasi-error of.
- Figure 5 is a diagram of the Geneus homo.
- the freeness of the mice grown in ()), 6) 5 was determined by a quantitative kit.
- the graph shows the mean quasi-error of 6A is a plot of the current R A.
- the present state of BRA mR A in Us's vessel was analyzed by Nozza Butti.
- the ap is the amount of RA that depends on.
- 6B is a diagram of the derivation of B VI RA in obese mice.
- FIG. 7B is a diagram related to an insult test of a geneus.
- Tg represents the Langusius.
- Fig. 7C is a diagram related to the ins test of the geneus.
- FIG. 7D is a diagram showing that BRA partially damages Insigna.
- the derived C2C 2 cells were intensified at the above-mentioned size, and the insemination of A Se 73 was determined by the standard. Good for carrying out Ming
- BRA was shown to be a novel mediator of inducing obesity-induced insulin.
- the BRA gusset is fully installed due to the weaving of the activated cushion.
- Ming's lawn was born according to Mende's law, and if this is the case, it is possible to obtain the same litter of the present subject (that is, () () 's). There is a result that can be done.
- non-human foods such as mousse, rat, peach, rabbit, pig, dog, nes, sheep, etc. can be mentioned. Soy sauce is preferred, and more preferred is mousse.
- Akira Hit shows the instinct when he is obese. Also, when you become obese,
- the number of classes is reduced.
- gene analysis using the tissue of obesity suggests that there is a large amount of white-induced trafficking in obesity-related diseases.
- the loss of BR which has sex with Akira and Kufa, was significantly reduced, resulting in a significant reduction in the number of guages in the obese state, which resulted in no indication of insufficiency in the fully-fed state.
- the weight of obesity is higher than that when normal foods are fed to animals of the same gene by feeding high weights to chickens. 8 or more, and more preferably 2 or more).
- a state-us can be obtained, for example, by allowing D2 (Quar) to have a premium of 2 for a female of 6 and above, but is not limited thereto.
- BRA knockout (BRA)
- a gene fragment is obtained from the Us gene library by a method such as PCR, and the B gene (or a part thereof) is masked using this gene fragment. Then, using the DA technique, all of the skewed B gene is replaced with, for example, an isine gene, and then 5 is treated with, for example, a theaxin (DT) gene and a theta A fragment.
- DTA Gene Introduce the gene of simple swaze sanse (SV k) gene to fabricate a targeting vector. After (targeting) the prepared targeting vector, it is introduced into the ES cell by using the composition () and the homologous assembly is prepared. From the homologues selected, ES cells that show resistance to antibiotics such as G4 8 Shikubi (GA C) are selected. Here, it is preferable to confirm by Southern method, such as the selected S target object.
- the ES cell described above is returned to a pseudo-parental mouse, which is a mouse embryo of a mousse, and a dichotomy.
- a pseudo-parental mouse which is a mouse embryo of a mousse, and a dichotomy.
- a combined mouse B-us
- a BRA knockout B-us
- a BRA knockauus and a lumbus usus usususus
- a method in which DA is separated from the spleen of the spleen and confirmed by Southern examples include the method of isolating RA from the mouse brain and the like and confirming it by zambul, or confirming the expression of BRA in us by stub.
- a meal is taken and swallowed, and this mouse is fed for a predetermined period of time. Then shoot a shot. Then, it is confirmed that when the blood glucose is monitored over time, the blood glucose level is significantly lower than that of the control mouse (or littermate).
- the BRA knockouts obtained were used to make them obese.
- BRA antagonism was administered to animals other than the clear ones (the ones that did not lose the function of expressing BRA (hi)) by administering the quality of the I will try.
- the candidate traits have similar characteristics to those of the present invention, it means that the sex of BR is suppressed regardless of the expression of BR. Therefore, it can be determined that it is the administered B-state.
- it includes a BR method squeezing method using the above-mentioned Ming hee (hi) and hee (hi) other than ming's stuff.
- the BR status means a substance that binds to BR receptors in spheres and crofa and inhibits the sex of BRA, but by itself does not exert the W effect.
- the feature of the screen is, in particular, that it includes the steps () to (). Note that in the step (1), the order does not matter, and the shift may be performed first or at the same time. . 0 Humans and the process of putting the humans in the state (process) Administering quality to the humans)
- the animal As the animal, the animal of the same kind as the control animal, which has the same BR gene and whose BR gene has not been destroyed (the animal whose BR gene function has not been lost in color), is used. It is possible to use either wild type and / or BRA, or both. Hi, Akira no Hi (BR hee) It is preferable that they are littermates.
- the weight of the animal is higher than that in the case where the normal gene is taken by the chicken of the same gene by making the chicken take the high fee.
- a female in a state of 6 can be obtained by allowing a female of 6 above to obtain a premium of 2 such as D32 (qua), but is not limited thereto.
- slaughtered animals and slaughtered animals are put into the form, it is preferable that they are the same as those in the feed.
- Examples of candidates (for B anthase) to be administered to humans include various kinds of artificially synthesized naturally, tanks (including body), quats, and organic compounds.
- Examples of comparative evaluations in the process include, for example, a small number selected from the number of in-plants, white courage, and adipotinity. By comparing these evaluation targets with the control and the prepared ones, the BRA statement can be easily squeezed.
- control specimens and specimens (below, each specimen) are allowed to stabilize for a predetermined amount (for example, 6 of Us), and then the specimen is irradiated with an insulin solution. Then, the control and control animals are compared with those for which blood glucose tagging is desired over time. If this is not significant at this time, it can be evaluated as the desired BR anthrax after administration. If the test subject remained significantly higher, B-assessment can be evaluated.
- a weave of cotton is sampled and finely cut. After dissociating the fragmented tissue with various elements,
- test subject had a significantly large number of constants, it can be evaluated by the target B VI ass after administration.
- the knowledge in 2. above can be applied to the knowledge of the chair.
- you can use for example, Us Adipokti E SA Kit (Otsuka Pharmaceutical Co., Ltd.). Compare adipose and cutin to a certain adipo and cutin. If there is no significant difference, administer it.
- the target BRA antase can be evaluated.If the test substance has a significantly lower concentration, it can be evaluated by the target B antase administered.
- the squeaking method may include other steps in addition to the above, and is not limited. How to determine the effect of BRA ant
- the BRA anthase obtained from the above-mentioned screening shows excellent quality, it cannot be said to be useful if it has an adverse effect on the treated animal. Is. Except for the fact that Akira no Hi and the gene are defective, it is possible to remain unchanged in the wild and show no abnormal properties over the long term after birth. Therefore, when BR antus was administered to babies other than Akira's chickens and BR was in a non-functioning state as in Akira's chickens, the state of administration was compared to that of Akira's chickens. Suru At this time, if the test subject is found to have no effect (effect) on the control subject, it can be determined that BR antus has side effects related to the condition. Actions include, for example, survival and weight gain, hematopoietic activity, and effects of performance, and these can be used to determine the effects.
- the BR anthase is as described in the above, and is preferably obtained by the Sung method of the above ().
- the defining method is characterized by including the step ()).
- the process of comparing the human with the human () The process is explained below.
- test subject who administers B-assay is obese, but not limited thereto.
- the same explanation as in step (1) of the Skug method in () can be applied.
- BR Anthus can be taken orally and is not limited to and can be used in accordance with applicable law and regulations.
- the BRA assay may be administered in a pharmaceutically obtained hydrated state, or may be administered in a pharmaceutically obtained hydrate state without limitation.
- Examples of comparative evaluation in the process include survival and weight gain, hematopoietic activity, and a small number selected based on performance.
- the side effect of BRA antus can be easily assayed for the type and mode of action.
- test animals show no symptoms after administration of B-anthus and are tested for weight gain in the same manner as the control animals. Note that if the weight is lighter than that of the control and wild animals, weight gain will occur.
- the method tests that the test animals are still within the absolute range of the absolute (blood cells, neutrophils and phenotype) rates in the blood after administration of B-anthas. Although the number of in vivo uterine craps is lower than that of the test animals, it is possible to make a comparison with the above-mentioned animals effectively because no difference in the bone marrow cells is observed.
- the loss of the function of expressing BRA of Ming is devoid of the ability for the tissue profile. Therefore, as a result, it has characteristics such as a decrease in the number of white courage. Therefore, we will try to administer BRA mediators by administering quality to them using Akira no Hi (Hee). In the same manner as in the non-human animals (i), the administered animals showed signs of increase in the number of craps for the insulin, regardless of whether BR was expressed. The effect of BR is similar.
- the BRA medium means a substance having a specific migratory property to spheres and coufer, and a substance having the same property as BR.
- the features of the skip specifically, include the following steps (1) to (). Note that the steps (1) and () do not matter in the order, and the shift can be performed first or at the same time.
- an animal of the same kind as the tested animal, in which the BA gene has not been destroyed (animal in which the BR gene function has not been lost in the color body), can be used.
- the BA gene function has not been lost in the color body
- Hi, Akira no Hi (BRA Hide) It is preferable that they are littermates.
- the weight is -2 or more (more preferably -5 or more, more preferably -8 or more) as compared with the case where the normal gene is taken by the chicken of the same gene by making the chicken take the high fee. , And more preferably 2 or more).
- a state mus can be obtained, for example, by allowing a female mus on 6 to obtain a high price such as D32 (Claire) for 2, but is not limited thereto.
- slaughtered animals and slaughtered animals are put into a condition, it is preferable that the same thing be done for feed.
- Candidates (for BRA media) to be administered to humans include various artificially synthesized substances, tanks (including body), poqua, and organic compounds. It is possible to go and is not limited, and even if there is a gap, it is possible to adopt the public law and regulations. Also, it can be determined in consideration of the kind and condition of the test subject and the quality. Examples of comparative evaluations in the process include a small number selected from the number of isps, the number of white phages, and the degree of adiponectin. By comparing these evaluation targets with the test and target test specimens that were put into a state, the BIV media can be easily masked. The method of comparative evaluation is illustrated below.
- a test substance and a control substance (below, each substance) is allowed to stabilize at a predetermined level (for example, 6 for a mouse), and then an insult solution is irradiated. Then, the test specimen and the control specimen are compared with each other for blood glucose monitoring over time. If it is not significant at this time, it can be evaluated that it is the target drug administered. If the test subject remains significantly lower, it can be evaluated as having been administered and not of the desired quality.
- the weave of the fish is sampled and thinned. Then, after understanding each element of the fragmented tissue and understanding, only the curve is recognized. Measure the number of phages using a facet or a sorter, and compare it with the test specimen and the control specimen. If this is not significant, it can be evaluated as the desired BRA mediator after administration. On the other hand, when the constant was significantly decreased in the test animals, it can be evaluated that the dose was not the target quality. As for the knowledge, the explanation in section 2 can be similarly applied.
- Sculling method which may include other processes in addition to the above.
- the other steps include various steps that can be carried out in the method of screening a desired material using a knockout machine or the like. Below, the implementation will be described in more detail, but the present invention is not limited thereto.
- the genome sequence () of the us BRA gene was obtained from the us sequence (accession: AC 65347), which is available from the book data (www cb hgov).
- the base sequence of the B gene is the base sequence (7902 b) consisting of bases 72 78 to 18079 of the base sequence of the color body.
- Heating for 95g at 95C ⁇ : 95C (60sec) Ag 57C (60sec) ⁇ : 72C (60sec) is cycled for 40 seconds. .
- the oga piece was prepared by PCR using the genome D A of C57B 6 us as a template and the following ply and Ta pomerase Takara) under the following conditions and conditions. Prino
- the temperature was kept at 7 ° C and cooled at 4C.
- Chimeric mice were obtained by microimplanting the selected ES cells into R-us seedlings and transplanting them into CR-us mothers. By mating two BR genes born in the C57B 6 Usu sister,
- the tail pieces were processed overnight at 56 C in DA ff s C p 75 300 mm C 05 o P40 oe ase (0 g) 50. This was heated at 98C for 20 minutes, and then it was placed in 4 temps. Type) and Taq Pomerase Takara) were used to perform PCR with the following composition and conditions. Privacy
- the high-molecular-weight genomic DA RA was extracted by (It was put on the ybo desa. For the idea, a 32 dCTP sensitive probe was used, and the radiation signature was detected on the B3000 (Fim).
- R2 ply 0 is 0 5 1
- mice were exposed to 6 shots of either Insane (commercial company) (075 g) or Grape (commercial company) 075 mgg. Targeted by Test R (Academic Research Institute) after hours. FD32 (Quar) was used for rearing, and it was carried out for 6 or more females over 6 hours. 4. E SA blood quality
- FCS FCS Us gG (g) 0 g in PBS was allowed to do 30 on ottin a (70 BD fus) g). Twenty volumes of 5 CS PBS was added, and the mixture was allowed to stand on TC Spavidi (BD phenyl) 0) water for 30 in 5 CSPBS. 20 quantity of 5. Add CS PBS, PBS containing Po de (g) was suspended in 2 g and the cell density was measured by ACS BD.
- the wall weave was set with 4 homemade PBS and then lined. 6) to Ochin 480 (B 8,
- Sp-avid (BD fagin) identified with horseradish oxidase in PBS (10 g at room temperature for 30) and then developed with dianochrome to develop color.
- the BRA () and the litter of the same were given to induce the experiment.
- the () us group continued to gain weight, but the average () () us group was always 20 higher than the (2B2C) () us group. Since the weight gain () was changed (), it is presumed that it was not due to weight and appetite.
- the weaving weeds were used to compare the percentage of weaves per body weight, and there was no significant difference between the () uss and the control uss. Look at the () uss
- White weave fat in uss causes abnormalities in individual knots.
- blood glucose was usually () Uus, but in the raised group, it was elevated (4A) o In () Usus, blood glucose was elevated as compared to normal blood glucose.
- the number of () us that was growing normally was reduced to 49 of () () us (5A).
- the values increased 2 ⁇ 7 in the () () us group and 98 times in the () us group, respectively.
- the expression of BR mRA in the us was analyzed.
- BRARA was synthesized in brain, lung, and bone marrow (6A).
- Ming it was shown that BRA mRA was also expressed in the uterus, white tissue, and tissue in addition to them (6A).
- the BRA RA of the () us weaves grown was about 5 times increased (6B).
- the T mR A level also increased. Therefore, the BRA is considered to be a member of the Adipokai gene that is fully transcribed.
- adipectin acts on liver muscle to enhance calcification through sexualization of PPA (Ya ac T ea ⁇ , a ed Vo18 8, p 288 295 2002) Ya ac et al. Administer adipontin to genetic Aus. Reported that the obesity was not improved but the amount was improved (Ya ac T e ⁇ a ed Vo 7 94 946 2,000) o BRA () It is presumed that the reason why the above-mentioned state did not occur was due to the use of adipotectin. It shows that the usability of the weaving that has been proposed so far and the profitability of the issuance are supported, and that the organizational capacity via BRA is essential for the issuance. Obesity models reported so far (experimental
- BR is a molecule discovered in the expressed XC chi, and it is clear that B knockout is also useful in the investigation of the immune system of cancer. If the B knockout is sold, it is thought that researchers around the world who are interested in the life and cancer of the drug will obtain it and upgrade it to the theoretical function of BRA. It is expected that this uss will be accompanied by the exhibition of research.
- the cD A base sequence (12) report containing SBR A was obtained from (S ee a Ae amo Vo 2 p 677689 2000). This base sequence (12) is published on the book database (www cb gov) with the accession: A44754.
- B AC B Ce ado oc y e ac va g C e ok e described in the document corresponds to BRA in this specification. Is.
- the 300 bp 13 of the open frame shows the column A.
- C2 2 obtained from the official link.
- Spe Sc F s S a dcD Killadam mixer (Invisibility) was used to synthesize one cDA, and RTPCR (Reve seT a sc ase Po y e aseC a Reac o).
- the produced D A piece was microinjected into the C57B 6 mouse embryo. From the mousse obtained by transplanting the eggs containing D A into the pseudo-us palace, we selected the ones containing the target D A pieces, and used this as the first generation C BRA Rasius.
- C2C12 obtained from a concrete tank, was cultivated at 4 D beccos od esEages e (D E) land to induce oxidization.
- D E D beccos od esEages e
- the myocytes were treated with 100 Us BRA (R DSys e s) and further supplemented with 0 Is and stimulated at 37C.
- BRA was not used, and BRA was also added.
- These cells were thawed and 20 tank compounds were subjected to SDS aqua and subjected to Western analysis with Se 473 and (Ce S ag).
- PB proteinase B
- PB proteinase B
- the number of courages of the grown BRA quaau CB Langsickus is It was 44 less than the number of quadruple Quars raised. Although this does not indicate that the BRA-induced guidance in obesity is a full contributor to the disease, the BRA does indicate that the crew members have a different sex. . This was attached by the results of experiments in which BRA directly impairs the insulin signatures for C2C 2 cells.
- the knockout object in which the BRA gene was destroyed that is, the lost object of BRA CXC 4 is provided. It is extremely useful for clarification of cerebral BAR of white globules, white globules and quats, and for urinary BAR of 2 urinary diseases that are mainly caused by insulin.
- Ming a method of skating BR Antas will be provided. Singing of Ming By using a substance of the present invention that can survive for a long period of time and a control substance (in both states), it is possible to easily evaluate that the candidate substance is the BRA substance ant. It is useful. In addition, Ming provides a method for determining the action of BR anatase using Ming lantern control lantern.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne un animal non humain à inactivation du gène BRAK. Cet animal non humain à inactivation du gène BRAK se caractérise en ce que le gène BRAK y a été neutralisé.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-352519 | 2005-12-06 | ||
JP2005352519 | 2005-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007066794A1 true WO2007066794A1 (fr) | 2007-06-14 |
Family
ID=38122936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/324622 WO2007066794A1 (fr) | 2005-12-06 | 2006-12-05 | Animal non humain a inactivation du gene brak |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007066794A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008096905A1 (fr) * | 2007-02-09 | 2008-08-14 | Tokyo Metropolitan Organization For Medical Research | Anticorps monoclonal humain anti-brak (cxcl14) et son utilisation |
JP2012012330A (ja) * | 2010-06-30 | 2012-01-19 | Kanagawa Dental College | 癌転移抑制剤及び医薬組成物 |
US8981899B2 (en) | 2007-07-18 | 2015-03-17 | Iloq Oy | Electromechanical lock |
-
2006
- 2006-12-05 WO PCT/JP2006/324622 patent/WO2007066794A1/fr active Application Filing
Non-Patent Citations (3)
Title |
---|
DUFOUR H.J. ET AL: "IFN-gamma-inducible protein 10 (IP-10; CXCL10) -deficient mice reveal a role for IP-10 in effector T cell generation and trafficking", JOURNAL OF IMMUNOLOGY, vol. 168, no. 7, 2002, pages 3195 - 3204, XP003013694 * |
HROMAS R. ET AL: "Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus maligant cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 225, no. 3, 1999, pages 703 - 706, XP003013692 * |
NAGASAWA T. ET AL: "Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1", NATURE, vol. 382, 1996, pages 635 - 68, XP003013693 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008096905A1 (fr) * | 2007-02-09 | 2008-08-14 | Tokyo Metropolitan Organization For Medical Research | Anticorps monoclonal humain anti-brak (cxcl14) et son utilisation |
US8981899B2 (en) | 2007-07-18 | 2015-03-17 | Iloq Oy | Electromechanical lock |
JP2012012330A (ja) * | 2010-06-30 | 2012-01-19 | Kanagawa Dental College | 癌転移抑制剤及び医薬組成物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hinrichs et al. | Growth hormone receptor-deficient pigs resemble the pathophysiology of human Laron syndrome and reveal altered activation of signaling cascades in the liver | |
Kubota et al. | Insulin receptor substrate 2 plays a crucial role in β cells and the hypothalamus | |
Rowland et al. | In vivo analysis of growth hormone receptor signaling domains and their associated transcripts | |
Leone et al. | PGC-1α deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis | |
Ohtsubo et al. | Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes | |
Lin et al. | Dysregulation of insulin receptor substrate 2 in β cells and brain causes obesity and diabetes | |
Bartke et al. | Life extension in the dwarf mouse. | |
Nara et al. | Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance | |
Hinrichs et al. | Growth hormone receptor knockout to reduce the size of donor pigs for preclinical xenotransplantation studies | |
Ganguly et al. | Glucose transporter isoform-3 mutations cause early pregnancy loss and fetal growth restriction | |
Geiser et al. | The zinc transporter Zip5 (Slc39a5) regulates intestinal zinc excretion and protects the pancreas against zinc toxicity | |
Horvath et al. | Uncoupling proteins-2 and 3 influence obesity and inflammation in transgenic mice | |
Liu et al. | Thymus-associated parathyroid hormone has two cellular origins with distinct endocrine and immunological functions | |
Binart et al. | A short form of the prolactin (PRL) receptor is able to rescue mammopoiesis in heterozygous PRL receptor mice | |
Agnew et al. | A Wars2 mutant mouse model displays OXPHOS deficiencies and activation of tissue-specific stress response pathways | |
Wassif et al. | HEM dysplasia and ichthyosis are likely laminopathies and not due to 3β-hydroxysterol Δ14-reductase deficiency | |
Jiao et al. | Mex3c regulates insulin-like growth factor 1 (IGF1) expression and promotes postnatal growth | |
Wang et al. | Epimorphin–/–mice have increased intestinal growth, decreased susceptibility to dextran sodium sulfate colitis, and impaired spermatogenesis | |
Sperandeo et al. | Slc7a7 disruption causes fetal growth retardation by downregulating Igf1 in the mouse model of lysinuric protein intolerance | |
WO2007066794A1 (fr) | Animal non humain a inactivation du gene brak | |
US20060014178A1 (en) | Use of Mrf-2 for screening and therapies | |
US20110265194A1 (en) | Them5-modified models of non-alcoholic fatty liver disease | |
Jaehnig et al. | Increased susceptibility to isoproterenol-induced cardiac hypertrophy and impaired weight gain in mice lacking the histidine-rich calcium-binding protein | |
Kong et al. | Kill two birds with one stone: making multi-transgenic pre-diabetes mouse models through insulin resistance and pancreatic apoptosis pathogenesis | |
US8502016B1 (en) | Genomic alpha synuclein transgenic animal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06834377 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |